Novel agents and emerging treatment strategies in multiple sclerosis. What role for Cladribine?

Francesca Bagnato, Istvan Pirko

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Multiple sclerosis (MS), a chronic inflammatory-degenerative illness of the central nervous system (CNS), remains at the moment a treatable but incurable disease. Currently available disease-modifying agents (DMA-s), the majority of which are being injected, mainly relieve the inflammatory phase of MS with little beneficial effect, if any, in halting neurodegeneration. Cladribine is an immunosuppressive agent that can be administered orally and by cycles of short-course dosing as opposed to continuous administration. Cladribine has been shown to be effective in reducing inflammatory activity of MS but much remains unknown regarding its potential beyond the control of CNS inflammation. In addition, knowledge on the safety profile of cladribine in MS is limited. Data from on going clinical studies and registries on its safety profile will shed more light on the actual benefit/risk ratio of cladribine.

Original languageEnglish (US)
Pages (from-to)425-439
Number of pages15
JournalClinical Medicine Insights: Therapeutics
Volume3
DOIs
StatePublished - Jan 1 2011

Keywords

  • Cladribine
  • Disease modifying therapies
  • Infammation
  • Magnetic resonance imaging
  • Multiple sclerosis
  • Neurodegeneration

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Novel agents and emerging treatment strategies in multiple sclerosis. What role for Cladribine?'. Together they form a unique fingerprint.

  • Cite this